A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
This study has been withdrawn prior to enrollment.
(Lack of enrollment)
First Posted: January 7, 2011
Last Update Posted: February 2, 2017
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Study Status:||This study has been withdrawn prior to enrollment.|
|Estimated Study Completion Date:||February 2017|
|Estimated Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|